Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients

Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients

Background Immune checkpoint blockade has emerged as a highly effective treatment for patients with metastatic melanoma and cutaneous squamous cell carcinoma. Nivolumab blocks the interactions between programmed cell death protein 1 and programmed death ligand 1 allowing for activation of a latent i...

Full description

Bibliographic Details
Main Authors:	Richard Carvajal, Yvonne Saenger, Matthew Ingham, Shaheer Khan, Diana McDonnell, Shana M Coley, Geoffrey Dube, Faramarz H Samie, Larisa J Geskin, Daniel Brouder
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-06-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/8/1/e000908.full

Similar Items

Correction: Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients
by: Lisa Zimmer, et al.
Published: (2021-01-01)

Severe recalcitrant cutaneous eruption with dual immune checkpoint blockade
by: Sakeena Fatima, BA, et al.
Published: (2018-04-01)

Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma
by: Nicolas Jacquelot, et al.
Published: (2017-08-01)

Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade
by: David M. Miller, MD, PhD, et al.
Published: (2017-09-01)

Immune checkpoint inhibitor therapy in a liver transplant recipient with autoimmune disease and metastatic cutaneous squamous cell carcinoma
by: Caitlin M. Brumfiel, MS, et al.
Published: (2021-08-01)

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
by: Jake S. O’Donnell, et al.
Published: (2016-10-01)

Neutrophils in the era of immune checkpoint blockade
by: Solange Peters, et al.
Published: (2021-07-01)

Immune-Checkpoint Blockade Therapy in Lymphoma
by: Ayumi Kuzume, et al.
Published: (2020-07-01)

Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?
by: Anja Wessely, et al.
Published: (2020-12-01)

Treatment of metastatic cutaneous squamous cell carcinoma in a solid organ transplant recipient with programmed death-1 checkpoint inhibitor therapy
by: O'Connell, K.A, et al.
Published: (2022)

CANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS
by: A. V. Bogolyubova, et al.
Published: (2015-10-01)

Rethinking immune checkpoint blockade: ‘Beyond the T cell’
by: Xiuting Liu, et al.
Published: (2021-01-01)

Immune Checkpoint Blockade for Aspergillosis and Mucormycosis Coinfection
by: Jan Christoph Banck, et al.
Published: (2021-03-01)

Acquired Resistance to Immune Checkpoint Blockade Therapies
by: Xianda Zhao, et al.
Published: (2020-05-01)

The Role of Immune Checkpoint Blockade in Uveal Melanoma
by: Anja Wessely, et al.
Published: (2020-01-01)

Gastric Cancer in the Era of Immune Checkpoint Blockade
by: Lucía Figueroa-Protti, et al.
Published: (2019-01-01)

Smoldering myocarditis following immune checkpoint blockade
by: Timothy G. Norwood, et al.
Published: (2017-11-01)

Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle
by: Maria A.V. Marzolini, et al.
Published: (2015-03-01)

Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
by: Brian J. Ahn, et al.
Published: (2013-11-01)

Predictive biomarkers for tumor immune checkpoint blockade
by: Tong M, et al.
Published: (2018-10-01)

The role of neoantigen in immune checkpoint blockade therapy
by: Ming Yi, et al.
Published: (2018-11-01)

Epigenetic checkpoint blockade: new booster for immunotherapy
by: Ziqiao Wang, et al.
Published: (2021-07-01)

The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma
by: Hong Yuan, et al.
Published: (2021-03-01)

Dual checkpoint inhibitor-associated eosinophilic enteritis
by: J. Yang, et al.
Published: (2019-11-01)

Predictors of responses to immune checkpoint blockade in advanced melanoma
by: N. Jacquelot, et al.
Published: (2017-09-01)

Metabolomic adaptations and correlates of survival to immune checkpoint blockade
by: Haoxin Li, et al.
Published: (2019-09-01)

An immunomodulatory signature of responsiveness to immune checkpoint blockade therapy
by: Hongru Shen, et al.
Published: (2020-12-01)

New development of Immune checkpoints blockade in cancer immunotherapy
by: Wu Feixuan
Published: (2019-01-01)

Photothermal therapies to improve immune checkpoint blockade for cancer
by: Preethi B. Balakrishnan, et al.
Published: (2020-12-01)

Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs
by: Maureen L. Drakes, et al.
Published: (2020-11-01)

Prospects for combining immune checkpoint blockade with PARP inhibition
by: Anping Li, et al.
Published: (2019-09-01)

Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma
by: Na Zhang, et al.
Published: (2020-11-01)

Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
by: Elisa Peranzoni, et al.
Published: (2020-07-01)

Combination immune checkpoint blockade as an effective therapy for mesothelioma
by: Vanessa S. Fear, et al.
Published: (2018-10-01)

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
by: Florent Petitprez, et al.
Published: (2020-05-01)

Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
by: Qingyang Xiao, et al.
Published: (2020-01-01)

Epigenetics modulates the complexity of the response to Immune Checkpoint Blockade
by: Isabel Barragan
Published: (2020-10-01)

Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer
by: Shravanti Macherla, et al.
Published: (2018-11-01)

Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
by: Michael Dougan
Published: (2017-11-01)

Immune checkpoint blockade therapy for bladder cancer treatment
by: Jayoung Kim
Published: (2016-06-01)